Two Roads Diverge For Mylan: Teva Or Perrigo
This article was originally published in The Tan Sheet
Executive Summary
Teva announced a proposal to acquire Mylan for $82 per share, or roughly $40 billion, putting Mylan’s independence and a proposal to acquire OTC drug specialist Perrigo in question. Adding to the uncertainty, Perrigo rejected Mylan’s offer after market close.
You may also be interested in...
Teva Changes Its Tune On Substitutable Generic Advair
Teva is aggressively developing a fully substitutable generic version of Advair and other AB-rated respiratory products now that FDA has released draft guidance on bioequivalence requirements for the inhaled respiratory drug.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.